Trial Profile
A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Metastatic Adenocarcinoma of the Breast
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Exatecan (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 17 Apr 2014 New trial record